Equities

Bone Biologics Corp

BBLG:NAQ

Bone Biologics Corp

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)1.59
  • Today's Change0.09 / 6.00%
  • Shares traded64.44k
  • 1 Year change-96.29%
  • Beta--
Data delayed at least 15 minutes, as of May 28 2024 20:59 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Bone Biologics Corporation is a developer of orthobiologic products for spine fusion markets. It is focusing development efforts for its bone graft substitute product on bone regeneration in spinal fusion procedures, while additionally having rights to trauma and osteoporosis applications. It is a medical device company that is focused on bone regeneration in spinal fusion using the recombinant human protein known as NELL-1. NELL-1 in combination with demineralized bone matrix (DBM), is an osteopromotive recombinant protein that provides target specific control over bone regeneration. Its platform technology is its NELL-1, a proprietary skeletal specific growth factor which is a bone void filler. NELL-1 provides regulation over skeletal tissue formation and stem cell differentiation during bone regeneration. The DBM Demineralized Bone Putty provided as part of the convenience kit with NELL-1/DBM is a Class II device. DBM Putty is a matrix composed of processed human cortical bone.

  • Revenue in USD (TTM)0.00
  • Net income in USD-6.10m
  • Incorporated2007
  • Employees2.00
  • Location
    Bone Biologics Corp2 Burlington Woods Dr Ste 100BURLINGTON 01803-4551United StatesUSA
  • Phone+1 (781) 552-4452
  • Fax+1 (845) 818-3588
  • Websitehttps://www.bonebiologics.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
SETO Holdings Inc4.96m-652.00k1.00m18.00--0.0911--0.2024-0.056-0.0560.39940.1341.572.658.51---20.703.84-29.075.9552.8352.44-13.153.920.99211.240.3040.0019.015.44-61.23------
Remedent Inc1.13m-259.38k1.10m16.00--0.2324--0.9743-0.013-0.0130.05650.23670.14743.452.69---3.247.35-5.2012.9365.3864.60-21.9721.200.2033-0.7720.00---33.63-21.70-140.31------
Invivo Therapeutics Holdings Corp0.00-9.33m1.24m6.00--0.1387-----3.53-3.530.002.870.00----0.00-81.32-73.69-94.35-85.63------------0.00-------6.01--19.74--
SPO Global Inc838.00k-540.00k1.27m2.00------1.51-85.99-85.99131.76-476.561.76-------113.56-305.39----31.1527.31-64.44-384.85---1.45-----17.09-15.1313.03------
Escalon Medical Corp11.65m-296.71k1.30m38.00--1.26--0.1114-0.0401-0.04011.290.22592.403.757.51306,456.30-1.26-1.76-2.84-3.6744.0744.57-0.5265-0.91140.8927-1.620.1584--13.801.33760.89-17.06-19.85--
Grapefruit USA Inc34.85k-4.37m1.44m9.00------41.28-0.008-0.0080.00006-0.01010.01211.310.22593,872.22-151.85-268.93-----1,304.65-10.09-12,531.68-408.870.0388-1.50-----83.9677.87-35.68------
Acutus Medical Inc9.55m-9.70m1.58m233.00------0.1656-0.33010.09560.3261-0.13530.12111.141.4640,974.25-12.30-46.76-14.84-56.88-24.07-89.12-101.56-773.492.89-4.641.13--136.3627.03-141.35---35.99--
Nemaura Medical Inc0.00-10.65m1.59m36.00---------0.3787-0.37870.00-0.61690.000.00--0.00-117.49-58.18---131.96-------7,384.830.0305-1.4710.81---84.71---1.85--64.14--
Kelyniam Global Inc517.70k-420.28k1.68m0.00--3.13--3.24-0.0253-0.02530.03120.01790.41357.044.38---33.57---41.79--18.86---81.18--1.26--0.6232---26.47---19.10------
Bone Biologics Corp0.00-6.10m1.75m2.00--0.4398-----23.10-23.100.003.620.00----0.00-114.93-98.31-189.37--------------0.00-------502.76------
VirExit Technologies Inc0.00-1.80m1.99m-----------0.0932-0.1130.00-0.03670.00-------6,103.43-----------------3.66-----100.00--19.08------
Aethlon Medical, Inc.574.25k-12.26m2.14m15.00--0.1448--3.73-5.03-5.030.23622.930.0369----38,283.33-78.62-75.30-92.02-84.98-----2,133.17-1,783.78----0.00--95.2130.86-15.55--106.99--
NanoVibronix Inc2.85m-3.20m2.16m10.00--0.6168--0.7583-1.72-1.721.451.260.5160.368313.64285,000.00-57.98-116.16-101.17-169.3668.9850.47-112.35-570.471.38-13.470.00--203.5948.3331.88---34.02--
Dynatronics Corp33.60m-5.14m2.22m154.00--0.298--0.0662-1.19-1.197.583.041.103.338.31218,173.30-14.35-6.02-19.94-8.3021.3727.33-13.07-4.550.6787-12.560.2188---8.41-8.81-19.84---5.11--
Data as of May 28 2024. Currency figures normalised to Bone Biologics Corp's reporting currency: US Dollar USD

Institutional shareholders

4.76%Per cent of shares held by top holders
HolderShares% Held
Armistice Capital LLCas of 31 Mar 202437.00k4.21%
Tower Research Capital LLCas of 31 Mar 20244.25k0.48%
UBS Securities LLCas of 31 Mar 2024600.000.07%
Wells Fargo Bank, NA (Private Banking)as of 31 Mar 20244.000.00%
Wells Fargo Securities LLCas of 31 Mar 20240.000.00%
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.